Safety First
This article was originally published in RPM Report
Executive Summary
The opening exchange between Covington & Burling attorney Paul Schmidt, representing Genentech, and FDA Division of Biologic Oncology Director Patricia Keegan, during the first day of the Avastin withdrawal hearing. (Excerpted by The RPM Report from FDA’s official transcript.)